The same urgency is not directed towards strengthening African laboratories
A new Bundibugyo Ebola strain has taken root in the Democratic Republic of the Congo, claiming 117 lives among 617 confirmed cases and crossing into Uganda — and yet the world's most powerful nations have responded not with sustained investment in African health systems, but with travel bans and quarantine demands that echo the inequities of the Covid-19 era. The tools to contain Ebola are well understood: contact tracing, isolation, protective equipment, and community trust — none of which are served by restricting movement or placing quarantine camps in countries with zero cases. What this outbreak reveals, once again, is not merely a viral emergency but a structural one: the chronic underfunding of African laboratories and surveillance systems that transforms manageable outbreaks into potential catastrophes. The question before the global community is whether this moment will finally break the cycle of panic and neglect, or simply repeat it.
- A Bundibugyo Ebola strain with no vaccine and no specific treatment has already surpassed every previous outbreak of its kind, spreading across the DRC and into Uganda with a fatality rate that kills roughly one in two people it infects.
- Western nations are responding with travel bans the WHO warns are counterproductive, and the US is pressing Kenya — a country with zero confirmed cases — to host a quarantine facility, prompting a court order to shut it down.
- The outbreak's invisibility in its early weeks was no accident: US aid cuts in 2025 gutted the regional detection infrastructure, and diagnostic tests for other Ebola strains simply do not identify Bundibugyo reliably.
- Contact tracing — the single most critical containment tool — has reached only 45 percent of known contacts in a conflict zone where community distrust runs deep, far short of the 90 percent threshold needed to stop the spread.
- A six-month, $500 million response plan has been launched, vaccine candidates are being fast-tracked, and global health leaders are demanding structural investment — but most of the funding remains unsecured and the window is narrowing.
Four years after Covid-19, the same patterns are surfacing. In May, a strain of Ebola called Bundibugyo began spreading through the Democratic Republic of the Congo. By early June it had infected 617 people and killed 117, already crossed into Uganda, and surpassed every previous Bundibugyo outbreak combined. There is no vaccine. There is no specific treatment. Patients receive only supportive care, and the virus kills roughly half of those it infects.
Bundibugyo is not the strain most people know. The 2014–2016 West African epidemic — caused by the Zaire strain — killed more than 11,000. Bundibugyo has caused only two prior outbreaks, both small. This one is different in scale, and experts fear it could grow worse. The virus likely jumped from an animal to a human weeks before anyone noticed, spreading invisibly in a conflict zone where early symptoms mimic malaria and cholera, and where diagnostic tests for other Ebola strains fail to identify it. When the Trump administration cut global health aid in early 2025, it removed much of the surveillance infrastructure that might have caught it sooner.
The wealthy world's response has been swift but misaligned. The United States sought to establish a quarantine facility at an air base in Kenya — a country with zero confirmed cases — prompting Kenya's high court to order it temporarily closed. Both the US and Canada imposed travel restrictions on affected regions, a measure the WHO warns hinders response efforts and drives people toward unmonitored routes, just as similar bans did during Covid. Health justice advocates and an open letter signed by prominent African scientists called the pattern familiar and damaging: urgency directed at containment theater rather than at the laboratories, surveillance systems, and healthcare workers that could actually stop the disease.
For South Africans, the immediate risk remains low. Ebola spreads only through direct contact with bodily fluids from someone who is visibly ill — not through the air. Experts at Stellenbosch University and the National Institute for Communicable Diseases confirm that without travel to the epicentre or healthcare exposure, the danger is very limited, and hospitals have isolation protocols in place.
What actually works is contact tracing, exit screening at airports, immediate isolation, and community trust — none of which are abundant right now. In the outbreak zone, only 45 percent of contacts have been traced; containment requires exceeding 90 percent. Protective equipment is in short supply. The Africa CDC and WHO launched a six-month, $500 million response plan on June 5, aiming to contain the outbreak by November. Most of that funding has not yet been secured. Vaccine candidates are being fast-tracked, with trials potentially beginning within months. But the scramble itself is the indictment: Bundibugyo was known, and it was left behind because it had not yet killed enough people to attract sustained investment. The question, as the Africa CDC director put it, is not whether the outbreak can be stopped — it can — but whether the world will choose to act before it becomes something far harder to stop.
Four years after Covid-19 reshaped the world, the same patterns are emerging again—but this time with Ebola. In May, a new strain called Bundibugyo began spreading through the Democratic Republic of the Congo, and by early June, it had infected 617 people and killed 117. The virus has already crossed into Uganda. Yet even as the outbreak grows, the global response is repeating the mistakes of the pandemic: Western nations are imposing travel bans on African countries, the United States is demanding a quarantine facility in Kenya—a country with zero confirmed cases—and the underlying infrastructure that might actually contain the disease remains chronically underfunded.
Bundibugyo is not the Ebola strain most people know. The 2014-2016 West African epidemic, which killed more than 11,000 people, was caused by the Zaire strain. Bundibugyo has caused only two previous outbreaks: Uganda in 2007 with 131 cases, and the DRC in 2012 with 38. This outbreak is already larger than both combined. The virus kills roughly half of those it infects—lower than Zaire's near-90 percent fatality rate, but still devastating. There is no vaccine. There is no specific treatment. Patients receive only supportive care: fluids, fever management, blood transfusions for severe bleeding. The only tools that work are the oldest ones: finding everyone who touched a sick person, isolating them, and keeping healthcare workers protected with gowns and masks.
The outbreak began in late April when a healthcare worker in Bunia fell ill and died. But she was almost certainly not the first case. The virus likely jumped from an animal—a bat or primate—to a human weeks or months before anyone recognized what was happening. Diagnostic tests designed for other Ebola strains do not work well for Bundibugyo; it requires specialized laboratory equipment to identify. Early symptoms mimic malaria, cholera, typhoid. In a conflict zone where people move constantly and healthcare surveillance has been gutted by funding cuts, the virus spread invisibly. When the Trump administration cut global health aid in early 2025, it removed a safety net that had previously supported Ebola detection in the region. By the time anyone noticed, the outbreak was already established.
The response from wealthy nations has been swift but narrow. The United States wants to establish a quarantine camp at Laikipia Air Base near Nanyuki, Kenya, about 190 kilometers north of Nairobi. The facility would allow Americans working in or passing through outbreak areas to be isolated in a controlled setting rather than evacuated to the United States. Kenya's high court ordered it temporarily closed, warning that housing Ebola patients in a country without a single confirmed case posed unacceptable risk to the public. President William Ruto later said refusing the US would seem ungrateful given American support for Kenyan healthcare. The United States and Canada have also restricted travel from affected regions—a move the World Health Organization warns is hindering the response. Research on Covid travel bans showed they delayed spread in some cases but did not stop it, while causing severe economic damage and often pushing people toward illegal travel routes.
Tian Johnson, a health justice activist in Johannesburg and founder of the African Alliance, sees something deeper in these decisions. "The issue is bigger than quarantine itself," he said. "It is about why the same urgency is not directed towards strengthening African laboratories, surveillance systems and the healthcare workforce." This week, an open letter signed by world health leaders—including South African scientists Helen Rees and Shabir Madhi—called for an end to the cycle of panic and neglect. "At a time when humanity can sequence pathogens in hours, develop vaccines in months, and deploy artificial intelligence across entire economies, the world already has many of the tools it needs," the letter read. "The question is whether leaders will choose to invest in and use them."
For South Africans, the risk remains low. There are nearly daily flights between Kinshasa and Johannesburg, but no confirmed cases have appeared in the country. Ebola spreads only through direct contact with bodily fluids—blood, vomit, saliva—from someone who is visibly, severely ill. It does not travel through the air. Jean Nachega, director of the Biomedical Research Institute at Stellenbosch University and an adviser to the African response, put it plainly: "This is not Covid-19. If you're not a healthcare worker, you did not travel to the epicentre, and you are here in South Africa, the risk is very, very low." If a traveler did develop symptoms, South African hospitals have protocols in place: separate entrances, isolation rooms, testing at the National Institute for Communicable Diseases, contact tracing for 21 days.
What works to stop Ebola is not travel bans but exit screening at airports, checking arriving travelers for signs of illness, immediate isolation, and thorough contact tracing. Yet the outbreak is occurring in an active conflict zone where contact tracing is difficult, where community distrust of healthcare workers runs deep, and where burial practices—mourners touching the body—create high risk of transmission. As of early June, only 45 percent of contacts had been traced. To contain the virus, that rate needs to exceed 90 percent. There is also a shortage of protective equipment: goggles, masks, overalls, face shields. The African Centres for Disease Control and the World Health Organization launched a six-month response plan on June 5, aiming to contain the outbreak by November. The plan costs more than $500 million. Much of that money has yet to be secured.
Vaccine development is underway. The Coalition for Epidemic Preparedness Innovations announced it was fast-tracking three candidates, with testing potentially beginning within months to a year. Scientists are also planning trials of treatments including remdesivir and obeldesivir. But this scramble highlights what should have happened years ago: proactive investment in vaccines and treatments for all known ebolaviruses before another outbreak struck. Almost all research focused on Zaire because it caused the most deaths. Bundibugyo was left behind. Now the world is playing catch-up. The Africa CDC director Jean Kaseya said the outbreak can be contained "very quickly" with the right support and actions. "This outbreak is serious," he said. "But it's not hopeless if we act." The question, as it was with Covid, is whether the world will choose to.
Citações Notáveis
The issue is bigger than quarantine itself. It is about why the same urgency is not directed towards strengthening African laboratories, surveillance systems and the healthcare workforce.— Tian Johnson, health justice activist and founder of the African Alliance
This is not Covid-19. If you're not a healthcare worker, you did not travel to the epicentre, and you are here in South Africa, the risk is very, very low.— Jean Nachega, director of the Biomedical Research Institute at Stellenbosch University
A Conversa do Hearth Outra perspectiva sobre a história
Why does it matter that this is Bundibugyo and not Zaire? Aren't they both deadly?
Bundibugyo kills about half of those infected. Zaire kills nine in ten. But the real difference is that we have a vaccine for Zaire and we've studied it for years. Bundibugyo has caused only two small outbreaks before this one. We know almost nothing about it.
So the US quarantine facility in Kenya—that's not actually about protecting Kenya?
Kenya has zero cases. The facility is for Americans. It's efficient for the US, but it signals something: that wealthy countries will invest in protecting their own citizens while the infrastructure in the outbreak zone itself remains starved for resources.
The letter mentions that we can sequence pathogens in hours now. Why couldn't we catch this outbreak sooner?
We could have, if the diagnostic equipment and trained people were there. But funding was cut. The outbreak spread for weeks in a conflict zone where people didn't trust healthcare workers and early symptoms looked like malaria. By the time anyone tested for Ebola, it was already established.
Travel bans didn't work in Covid. Why are countries doing it again?
Because it feels like action. It's visible, it's immediate. But it damages economies, pushes people toward illegal routes, and doesn't actually stop the virus. What works is screening people as they arrive, isolating the sick, and tracing contacts. That's harder and less dramatic.
Is South Africa in real danger?
No. Ebola needs direct contact with bodily fluids from someone who is visibly sick. It doesn't float through the air. If you're not a healthcare worker and you didn't travel to the outbreak zone, your risk is very low. But a traveler could arrive with symptoms, and then the system has to work.
What would actually stop this?
Money, mainly. The response plan costs over $500 million and most of it hasn't been secured. You need contact tracers, protective equipment, healthcare workers who are trusted. You need to trace 90 percent of contacts. Right now they're at 45 percent. And you need to do it in a war zone.